- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004278
Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection
OBJECTIVES:
I. Evaluate the efficacy of ganciclovir (12 mg/kg per day) versus no treatment in neonates with symptomatic congenital cytomegalovirus infection with central nervous system disease.
Study Overview
Detailed Description
PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by participating institution.
Patients are randomly assigned to no antiviral therapy or intravenous ganciclovir every 12 hours for 6 weeks.
Patients are followed at weeks 1-4 and 12, months 6, 12, 24, 36, 48, and 60, and yearly thereafter until puberty (when possible).
Study Type
Enrollment
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Symptomatic cytomegalovirus (CMV) infection: Central nervous system disease, with or without other organ system involvement, e.g.: Microcephaly, i.e., less than 5% for age Radiologic changes indicating brain disease Cerebrospinal fluid exam abnormal for age Chorioretinitis Hearing defects
- CMV confirmed by urine, throat, buffy coat, and/or conjunctiva culture
- No hydroencephalopathy or other devastating brain involvement
--Prior/Concurrent Therapy--
- No concurrent antiviral agent No concurrent immune globulin
--Patient Characteristics--
- Age: Under 1 month (preferably under 2 weeks)
- Life expectancy: No imminent demise
- Renal: Creatinine no greater than 1.5 mg/dL
- Other: Birth weight at least 1200 g Gestational age at least 32 weeks No HIV infection No concurrent bacterial infection Eligible if resolved following 2-week treatment and CMV symptoms persist
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
Collaborators and Investigators
Investigators
- Study Chair: Richard J. Whitley
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Disease Attributes
- DNA Virus Infections
- Herpesviridae Infections
- Infections
- Communicable Diseases
- Cytomegalovirus Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Ganciclovir
- Ganciclovir triphosphate
Other Study ID Numbers
- 199/11689
- NIAID-558607
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus Infections
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMaternal Cytomegalovirus Infections | Cytomegalovirus CongenitalUnited States
-
University of Sao Paulo General HospitalCompletedCytomegalovirus DiseaseBrazil
-
Mayo ClinicCompletedCytomegalovirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus InfectionUnited States, France, Germany, Italy, Japan, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Institut PasteurCompletedCongenital Cytomegalovirus InfectionFrance
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionsUnited States, Australia, Canada, Finland, Israel, Russian Federation, Spain
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
Clinical Trials on ganciclovir
-
National Center for Research Resources (NCRR)UnknownCytomegalovirus InfectionsUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Johns Hopkins Bloomberg School of Public HealthCompletedHIV Infections | Cytomegalovirus RetinitisUnited States
-
University of Oslo School of PharmacyTerminatedAcute Renal Failure | Cytomegalovirus Infections | Multi Organ FailureNorway
-
Peking University People's HospitalUnknownCytomegalovirus Infections
-
Salvador Gil-VernetRoche Pharma AGCompletedCytomegalovirus InfectionSpain
-
Singapore National Eye CentreActive, not recruitingCytomegalovirus InfectionsSingapore
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Completed
-
University Health Network, TorontoCompletedCytomegalovirus ViraemiaCanada
-
Fred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingAcute Respiratory FailureUnited States